Valuation: Alector, Inc.

Market Cap 167M 146M 134M 124M 233M 16.04B 238M 1.61B 631M 7.85B 625M 612M 27.04B P/E 2026 *
-1.75x
P/E 2027 * -2.34x
Enterprise Value -80.6M -70.43M -64.99M -59.91M -113M -7.76B -115M -777M -306M -3.8B -303M -296M -13.09B EV / Sales 2026 *
-11.8x
EV / Sales 2027 * -6.99x
Free-Float
86.82%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day+2.04%
1 week-6.83%
Current month-25.37%
1 month-3.85%
3 months-41.63%
6 months-18.48%
Current year-3.85%
1 week 1.37
Extreme 1.37
1.61
1 month 1.37
Extreme 1.37
2.14
Current year 1.37
Extreme 1.37
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
35.14
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 2013-04-30
Director of Finance/CFO 52 2025-06-19
Chief Tech/Sci/R&D Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 72 2024-03-18
Chairman 77 2023-06-12
Director/Board Member 72 2018-09-30
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Free

Controller/Auditor

20,000 0.0180%
6/17/26 Free

Director

38,150 0.0344%
6/17/26 Free

Director

38,150 0.0344%
Change 5-day change 1-year change 3-year change Capi.($)
+2.04%-6.83%-10.18%-77.24% 167M
-7.17%-4.39%+45.51%+79.00% 52.1B
+0.24%-1.54%+53.22%+71.85% 53.83B
+0.80%-6.31%+3.98%+423.29% 23.48B
-0.09%-0.01%-17.62%-14.67% 23.13B
-5.95%-2.58%+30.67%-9.58% 19.36B
-1.14%+0.03%+31.57%-30.42% 17.56B
-5.16%-7.00%+168.44%+306.37% 15.2B
-6.91%-5.83%+26.53%+636.97% 14.83B
+0.43%-1.03%+24.63%+191.40% 14.06B
Average -2.29%-3.04%+35.68%+157.70% 23.37B
Weighted average by Cap. -2.80%-2.36%+40.09%+143.95%

Financials

2026 *2027 *
Net sales 6.86M 5.99M 5.53M 5.1M 9.61M 660M 9.82M 66.09M 26M 323M 25.75M 25.19M 1.11B 22.88M 20M 18.45M 17.01M 32.06M 2.2B 32.77M 221M 86.75M 1.08B 85.93M 84.05M 3.72B
Net income -94.11M -82.24M -75.89M -69.95M -132M -9.06B -135M -907M -357M -4.44B -353M -346M -15.28B -96.62M -84.43M -77.91M -71.82M -135M -9.3B -138M -931M -366M -4.56B -363M -355M -15.69B
Net Debt -247M -216M -199M -184M -346M -23.8B -354M -2.38B -937M -11.66B -928M -908M -40.13B -326M -285M -263M -243M -457M -31.43B -467M -3.15B -1.24B -15.39B -1.23B -1.2B -52.99B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
26-07-17 $1.500 +2.04% 500,157
26-07-16 $1.470 -2.00% 713,579
26-07-15 $1.500 +7.91% 719,640
26-07-14 $1.390 -7.95% 529,650
26-07-13 $1.510 -6.21% 775,930
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.500USD
Average target price
3.100USD
Spread / Average Target
+106.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock